BOSTON — Compared with 17,800 patients starting new inhaled COPD maintenance therapy in 2016, 32,558 patients started a new inhaled treatment in 2022, according to a presentation at the CHEST ...

Opens in a new tab or window There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

has been approved since 2020 in the US as a maintenance treatment used to reduce exacerbations in people living with chronic obstructive pulmonary disease (COPD). Sales of Breztri were $677 ...

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Pulmonologists expecting to see an increase in individuals with respiratory issues due to the ongoing fires in Los Angeles County have added time for patients to their clinic schedules, Cedars-Sinai ...

More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).